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Background: Diabetes mellitus (DM) is a common serious health problem. Medication adherence is a key
determinant of therapeutic success in patients with diabetes mellitus. The purpose of this study was to assess
medication adherence and its potential association with beliefs and diabetes – related knowledge in patients with
type II DM.
Methods: This study was carried out at Al-Makhfia governmental diabetes primary healthcare clinic in Nablus,
Palestine. Main outcome of interest in the study was medication adherence. The Beliefs about Medicines
Questionnaire (BMQ) was used to assess beliefs. Morisky Medication Adherence Scale (MMSA-8©) was used to assess
medication adherence. The Michigan diabetes knowledge test (MDKT) was used to assess diabetes – related
knowledge. Univariate and multivariate analysis were carried out using Statistical Package for Social Sciences (SPSS 20).
Results: Four hundred and five patients were interviewed. The mean ± SD age of the participants was 58.3 ± 10.4
(range = 28 – 90) years. More than half (53.3%) of the participants were females. Approximately 42.7% of the study
sample were considered non-adherent (MMAS-8© score of < 6). Multivariate analysis showed that the following
variables were significantly associated with non-adherence: disease-related knowledge, beliefs about necessity of
anti-diabetic medications, concerns about adverse consequences of anti-diabetic medications and beliefs that
medicines in general are essentially harmful. Diabetic patients with high knowledge score and those with strong
beliefs in the necessity of their anti-diabetic medications were less likely to be non-adherent ([O.R = 0.87, 95% CI of
0.78 – 0.97] and [O.R = 0.93, 95% of 0.88 – 0.99] respectively). However, diabetic patients with high concerns about
adverse consequences of anti-diabetic medications and those with high belief that all medicines are harmful were
more likely to be non-adherent ([O.R = 1.09; 95% C.I of 1.04 – 1.16] and [O.R = 1.09, 95% C.I of 1.02 – 1.16] respectively).
Conclusions: Beliefs and knowledge are important factors in understanding variations in medication adherence
among diabetic patients. The BMQ can be used as a tool to identify people at higher risk of non-adherence.
Improving knowledge of patients about their illness might positively influence their medication adherence.
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Diabetes mellitus (DM) is a common health problem
that has serious medical and economic consequences.
The world prevalence of diabetes among adults (aged
20–79 years) was estimated to be 6.4% in 2010 and will
increase to 7.7% by 2030 [1]. Between 2010 and 2030,
there will be a 69% increase in numbers of adults with
diabetes in developing countries and a 20% increase
in developed countries. It is striking that Arab world
(North Africa, Middle East, and Gulf area) will have the
second highest increase in percentage of people with
DM in 2030 compared to other parts of the world [1].
No reliable data about treatment outcomes, complica-
tions, and economic effects of diabetes mellitus are avail-
able from Middle East in general and from Palestine in
particular [2].
Medication adherence has important therapeutic and
economic consequences [3,4]. Medication adherence is
believed to be influenced by factors beyond the traditional
demographic and clinical factors [5,6]. For example, the
extended Self-Regulatory Model, which includes both ill-
ness and treatment beliefs, was successful in explaining
variations in medication adherence among patients with
certain chronic diseases [7]. Diabetes-related knowledge
have also been reported to influence both medication ad-
herence and glycemic control [8]. This suggests that there
is a complex model of demographic, clinical, knowledge
and behavioral factors that affect medication adherence.
Several studies were carried out in Palestine and Arab
world about medication adherence in general and among
diabetic patients in particular [9,10]. Unfortunately, none
of these studies investigated the influence of factors such
as disease-related knowledge or behavioral aspects on
medication adherence. Such factors are important given
the cultural differences between Arabs and Europeans or
Asians where most studies about influence of behavioral
and knowledge aspects on medication adherence were
carried out [6,11,12]. Beliefs about medicines and extent
of disease-related knowledge are different among differ-
ent cultures [13]. Therefore, the objective of this study
was to assess anti-diabetic medication adherence and its
potential association with beliefs and diabetes–related
knowledge among patients with type II DM attending a
primary healthcare clinic in Palestine.
Methods
Study design
This was a cross-sectional study for the purpose of
evaluating the association between beliefs about medi-
cines, diabetes-related knowledge, demographic and clin-
ical factors with medication adherence among Palestinians
with type 2 diabetes mellitus. The approach we followed
in this study was similar to that used by other scholars
who investigated the relationship between medicationadherence and other factors [14-17]. The research ap-
proach was based on using medication adherence as an
outcome (adherence versus non-adherence) while using
demographic, clinical, psychological factors as independ-
ent variables. The tools used in this study have been previ-
ously used by other investigators [14-21].
Study setting
Nablus is the largest city in north West-Bank of Palestine.
Residents of Nablus city are predominantly Arabs. The
study was carried out at Al-Makhfia governmental dia-
betes primary healthcare clinic in Nablus city. Al-Makhfia
center is the main governmental center that provides
care for diabetic patients with governmental insurance
in Nablus city. During the study period, the investigators
made daily visits to the diabetic clinic to recruit and inter-
view potential participants.
Sample population
This study included a convenience sample of adult
population. Participants were recruited from Al-Makhfia
diabetic clinics while waiting to be seen by their health
care providers. The inclusion criteria for this study were:
1) patients who reported having type 2 diabetes; 2) avail-
ability of a medical file at the diabetic clinic; 3) a history of
at least one year of diabetes mellitus; 4) currently being
under medical care for diabetes; and finally 5) willingness
to participate in this study. The main exclusion criterion
was physical and/or mental conditions that could interfere
with the participant’s ability to understand and/or answer
questions in any of the used scales.
Sample size
A previous study indicated that medication non-adherence
among Palestinian diabetic patients is in the range of 20 –
50% [9]. Therefore, the sample size was estimated based
on the following assumptions: a descriptive study with di-
chotomous outcome (adherence versus non-adherence),
rate of medication non-adherence to be as low as 20%,
confidence interval width of 10% and confidence limit to
be 95%. Therefore, an estimated sample of 385 diabetic
patients is needed for this study [22]. In order to minimize
erroneous results and increase the study reliability, the in-
vestigators recruited a total of 405 diabetic patients during
the study period between July 2012 and October 2012.
Ethical approval
This study was approved by the Palestinian Ministry of
Health and Institutional Review Board (IRB) at An-Najah
National University. The interviewer explained the purpose
of the study to each participant and a verbal consent was
obtained from the participants prior to the commencement
of the study. The participants were also informed that their
participation was voluntary and that they could withdraw
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participants were assured that their responses would be
treated in confidence and they were assured anonymity
through the use of strict coding measures. All information
was kept confidential. The study was carried out in full
compliance with the guidelines of good clinical practice of
the world assembly declaration of Helsinki and was ap-
proved by the university ethical committee.Recruitment procedure
A brief screening was conducted by investigators to
identify potential participants in the following manner:
every person in the waiting area of the diabetic clinic
was asked if he/she is willing to talk to the investigator.
If the person agreed to talk to the investigator for pos-
sible participation, then an informed consent was read
and obtained by the investigators. Once the verbal con-
sent was obtained, verification of inclusion and exclusion
criteria took place. The questionnaires required for the
study were presented and explained during this interview.
All participants completed the questionnaires in a private
area in the clinic.
The forms and questionnaires used in this study were:
1) demographic and clinical information about the partici-
pant, 2) Morisky Medication Adherence Scale (MMAS-8©)
to determine level of medication adherence, 3) Beliefs about
Medicines (BMQ) to assess beliefs of participants about
their medications; and 4) Michigan Knowledge scale to
gain information about diabetes-related knowledge among
participants.Instruments
Medication adherence
Adherence to anti-diabetic medications was measured
using Morisky Medication Adherence Scale (MMAS-8©)
[23]. Approval to use and translate the (MMAS-8©) into
Arabic language was obtained from the developer. The
translation was carried out according to standard forward
and backward method. The Arabic- translated version of
(MMAS-8©) was used in previous publication [9]. The
(MMAS-8©) consists of eight questions designed to meas-
ure medication adherence. The first 7 ones are Yes/No
questions while the last question is answered on a 5-point
Likert scale. One point is given for each sentence based on
the answer. In the first 7 questions, one point is given for
each “NO” answer except for question number 5 where
one point is given for the “YES” answer. For item number
8, one point is given for “never/rarely” item and zero point
is given for “all the time” item. The total MMAS-8© score
is the summation of the scores for the 8 questions. The
total score obtained ranges from 0–8. In this study, pa-
tients with a total score of MMAS-8© < 6 were considered
non-adherent.Beliefs about medicines
Beliefs about Medicines was assessed using Beliefs about
Medicines Questionnaire (BMQ); [11]. Approval to use
and translate BMQ was obtained from the developer.
Translation of BMQ was also carried out according to
the standard forward and backward method. BMQ con-
sists of two sections, general and specific. The Specific sec-
tion assesses patients’ beliefs about medications prescribed
for a particular illness and consists of two scales that
assess personal beliefs about the necessity and concerns
of prescribed medication for controlling their illness (5
statements for each scale). The General section deals
with more general beliefs about medicines and consists
of two scales, the General-overuse scale which addresses
views about the way in which medicines are used by physi-
cians (4 statements), and the General-harm scale which
assesses beliefs about the degree to which patients per-
ceive medicines as essentially harmful. Each statement has
five potential answers (strongly disagree, disagree, uncer-
tain, agree, and strongly agree). The answers are scored
from 1 (strongly disagree) to 5 (strongly agree). Points of
each scale are summed to give a scale score. Higher scores
indicate stronger beliefs in the concepts of the scale.
There are five statements in Specific-necessity and
Specific-concerns scales and therefore the total sum of
possible scores in these scales would range from 5 to 25.
Higher specific-necessity scores represent stronger per-
ceptions of personal need for the medication to maintain
health now and in the future. Higher specific-concerns
scores represent stronger concerns about the potential
negative effects of the medication. There are four state-
ments in the General-overuse and the General-harm
scales and therefore the total sum of possible scores in
these scales would range from 4 to 20. Higher scores on
the General-harm scale represent more negative views
about medicines as a whole and a tendency to see medi-
cines as fundamentally harmful and addictive poisons.
Higher scores on the General-overuse indicate more nega-
tive views about the way in which medicines are pre-
scribed and beliefs that they are overused by physicians.
Diabetes knowledge test
The brief diabetes knowledge test developed by the Michigan
Diabetes Research and Training Center (MDRTC) known
as Michigan diabetes knowledge test (MDKT) [24] was
translated into Arabic and used to assess the general
knowledge of the participants. Approval to use and trans-
late MDKT was obtained from the developer. The general
MDKT consists of 14 multiple choice questions with one
correct choice for each question. The Knowledge score is
determined by giving one point for each correct answer
and zero for the wrong answer or no response. Those who
get the highest scores are the most knowledgeable about
diabetes. The total knowledge scores ranges from 0 to 14
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general knowledge. The diabetes knowledge test is an
effective, efficient, and inexpensive way to obtain a gen-
eral assessment of a patient's knowledge about diabetes
and its care. Due to the fact that the test is short and its
reading level is that of the 6th grade level, the diabetes
knowledge test can usually be self-administered. More-
over, review of correct and incorrect items also can be
used to provide feedback to patients and creates oppor-
tunities for teachable moments [24].
Demographic and health information
This section of the questionnaire was designed to obtain
information about demographic data and health history
of the participants. This section included information
about age, gender, years of education, income, medical
history, and current anti-diabetic medications. The med-
ical history question was presented to the participant as
a list of nine illnesses with dichotomous (yes/no) response.
All the participants were asked to report all the medica-
tions that they use on chronic basis. The data reported by
the participants regarding their anti-diabetic medications
was validated through checking the computerized system
at the MOH which contained up-to-date information
about the patients and their medications.
Data management and statistical analysis
During the pre-analysis phase, the data were coded to
maintain confidentiality for all participants. Summative
score of the instruments was entered as a continuous
measure. Data were entered and analyzed using SPSS
(Statistical Package for the Social Sciences). Descriptive
statistics was carried out for all variables and expressed
as mean ± SD for continuous variables with normal distri-
bution and as median (inter-quartile range: Q1-Q3) for
non-normally distributed variables. Kolomogrov-Smirnov
test was used to test normality of the variables. Factors
associated with non-adherence (MMAS-8 score < 6) were
analyzed with binary logistic regression followed by mul-
tiple logistic regression analysis. The dependent variable
was non-adherence (coded as 1). Multiple logistic regres-
sion analysis was carried out using variables that showed
significance in univariate analysis. A p value of < 0.05 was
considered statistically significant. The relationship be-
tween non-adherence and any particular variable of inter-
est was evaluated by calculating an odds ratio (O.R) at
95% confidence interval (C.I).
Results
General characteristics of the study sample
During the study period, a total of 405 consecutive pa-
tients were recruited. The mean ± SD age of the partici-
pants was 58.3 ± 10.4 (range = 28 – 90) years. More than
half of the participants were females (216; 53.3%).Patients reported an average of 2.1 ± 1.6 additional
illnesses (median = 4; Q1 - Q3: 3 – 6). Hypertension
(187; 46.2%), and dyslipidemia (149; 36.8%) were the
most frequently reported additional illnesses in the
study sample. Patients reported an average of 1.8 ± 0.7
(median = 2; Q1 – Q3: 1 – 2) anti-diabetic medications
and 4.3 ± 2.1 (median = 5; Q1-Q3: 4 – 7) different medica-
tions taken on daily basis. One hundred and sixty eight pa-
tients (41.5%) reported taking ≥ 5 medications on a regular
basis. The mean duration of DM reported by the patients
was 7 ±6 (median = 8.5; Q1-Q3: 4 – 12 years). More than
half of the participants had ≤ high school education (334;
82.5%). Demographic and clinical characteristics of partici-
pants are presented in Table 1.Reported adherence and beliefs
The internal consistency of the MMAS-8© was satisfac-
tory (alpha = 0.7). Two hundred and thirty two (57.3%)
patients were considered adherent (MMAS-8© adher-
ence score ≥ 6) while 173 (42.7%) were non-adherent
(MMAS-8© adherence score < 6). More than one third
(38%) of the participants reported that sometimes they
forgot to take their anti-diabetic medications; 24.0% re-
ported that they did not take their medications on at
least one occasion in the two weeks before the inter-
view; 17.0% reported that they discontinued taking their
medications without telling their doctor when they felt
worse upon taking their medications; 33.1% reported
that they sometimes forgot to take their medications
with them when they traveled or left home; 91.4.0%
reported taking all their medications on the day before
the interview; 17.0% reported that they stopped taking
their medicines when they felt like their diabetic symp-
toms were under control; 34.6% reported feeling hassled
by their treatment plans; and finally 73.9% reported that
they had difficulty remembering to take all their medicines
at least once in a while (Table 2). Internal consistency
for the BMQ four subscales was acceptable and showed
values between alpha = 0.63 – 0.82. Scores for Specific-
necessity subscale were significantly higher than that for
Specific-concern scores [median (interquartile): 20 (16 – 21)
versus 14 (10–17); p < 0.001]. The medians (interquartile)
for General-overuse and General-harm subscale were 12
(10 – 14) and 10 (8 – 13) respectively. Participants en-
dorsed the belief that their medications are necessary for
their current health but they were concerned about be-
coming too much dependent on their medications. Fifty
one percent of the participants who endorsed belief that
medications are harmful were non-adherent. Finally, ana-
lysis of MDKT scores showed that the majority of the
participants (327; 80.7%) scored ≥ 7 out of a total score
of 14. The mean ± SD of the MDKT scores was 8.2 ± 2
and median (Q1 – Q3) of 8 (7 – 10).
Table 1 Univariate analysis of factors associated with non-adherence
Variable Total N = 405 Non-adherent N = 173 Adherent N = 232 Odds ratio with 95% CI P-value
Age 58.3 ± 10.4 59.0 ± 10.7 57.7 ± 10.2 1.0 (0.99 – 1.0) 0.21
Gender
0.58Male 189 (46.7%) 78 (45.1%) 111 (47.8%) Reference
Female 216 (53.3%) 95 (54.9%) 121 (52.2%) 1.1 (0.8 – 1.7)
Education
0.54
Illitrate 49 (12.1%) 23 (13.3%) 26 (11.2%) Reference
Primary 168 (41.5%) 73 (42.2%) 95 (40.9%) 0.9 (0.5 – 1.6)
Secondary 117 (28.5%) 52 (30.1%) 65 (28.0%) 0.9 (0.5 – 1.8)
College 71 (17.5%) 25 (14.5%) 46 (19.8%) 0.6 (0.3 – 1.3)
Marital Status
0.021Single 105 (25.9%) 55 (31.8%) 50 (47.6%) Reference
Married 300 (74.1%) 118 (68.2%) 182 (60.7%) 0.6 (0.4 – 0.9)
Disease knowledge score 8 (7 – 10) 8 (6 – 9) 9 (7 – 10) 0.8 (0.7 – 0.9) < 0.001
Duration of Diabetes Mellitus 8.5 ± 6.0 8.5 ± 5.8 8.5 ± 6.2 1.0 (0.96 – 1.0) 0.96
Presence of chronic diseases
0.02Yes 284 (70.1%) 132 (46.5%) 152 (53.5%) 1.7 (1.1 – 2.6)
No 121 (29.9%) 41 (33.9%) 80 (66.1%) Reference
Anti-diabetic therapy
0.34Monotherapy 144 (35.6%) 57 (32.9%) 87 (37.5%) Reference
Combination 261 (64.4%) 116 (67.1%) 145 (62.5%) 1.2 (0.8 – 1.8)
Insulin Use
0.32Yes 132 (32.6%) 61 (35.3%) 71 (30.6%) Reference
No 273 (67.4%) 112 (64.7%) 161 (69.4%) 0.8 (0.5 – 1.2)
Number of medications 4.3 ± 2.1 4.5 ± 2.1 4.1 ± 2.1 1.1 (1.0 – 1.2) 0.042
Specific -necessity score 18.5 ± 4.0 17.9 ± 4.1 19.0 ± 3.8 0.94 (0.9 – 1.0) 0.009
Specific- concern score 14.0 ± 4.3 15.2 ± 3.9 13.1 ± 4.3 1.1 (1.1 – 1.2) < 0.001
General – overuse score 12.0 ± 3.3 12.0 ± 3.3 12.0 ± 3.3 1.0 (0.94 – 1.1) 0.95
General – harm score 10.5 ± 3.7 11.5 ± 3.7 10.0 ± 3.7 1.1 (1.1 – 1.2) < 0.001
Abbreviations: C.I confidence interval.
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Univariate analysis (Table 1) showed that there was no sig-
nificant difference between adherers and non-adherers in
age, duration of illness, gender, education, anti-diabetic
regimen and use of insulin. However, there was a signifi-
cant association between non-adherence and marital sta-
tus, presence of other chronic illnesses, diabetes-related
knowledge, total number of chronic medications, specific-
necessity, specific-concern and general-harm scales. Mar-
ried participants and those with high diabetes-related
knowledge score were less likely to be non-adherent
([O.R = 0.6; 95% C.I of 0.4 – 0.9] and [O.R = 0.8; 95% C.I
of 0.7 - 0.9] respectively). Adherers have significantly
higher specific-necessity, lower specific-concern, and lower
general-harm scores compared to non-adherers. Multi-
variate analysis (Table 3) showed that the followingvariables were significantly associated with non-adherence:
disease-related knowledge, beliefs about necessity of
anti-diabetic medications, concerns about adverse con-
sequences of the chronic use of anti-diabetic medications
and beliefs that medicines in general are essentially
harmful. Diabetic patients with high knowledge score
and those with strong beliefs in the necessity of
anti-diabetic medications were less likely to be non-
adherent ([O.R = 0.87, 95% CI of 0.78 – 0.97] and
[O.R = 0.93, 95% of 0.88 – 0.99] respectively). How-
ever, diabetic patients with high concerns about ad-
verse consequences of anti-diabetic medications and
those with high belief that all medicines are essen-
tially harmful were more likely to be non-adherent
([O.R = 1.09; 95% C.I of 1.04 – 1.16] and [O.R = 1.09,
95% C.I of 1.02 – 1.16] respectively).
Table 2 Self-reported medication adherence behavior of
study participants as determined by the Morisky 8-Item
Medication Adherence Scale (MMAS-8©)
Item Number (%) of patients
who answered yes
Do you sometimes forget to take your
[health concern] pills?
154 (38.0%)
People sometimes miss taking their
medications for reasons other than
forgetting. Thinking over the past two weeks,
were there any days when you did not take
your [health concern] medicine?
97 (24.0%)
Have you ever cut back or stopped taking
your medication without telling your doctor,
because you felt worse when you took it?
69 (17.0%)
When you travel or leave home, do you
sometimes forget to bring along your [health
concern] medication?
134 (33.1%)
Did you take your [health concern] medicine
yesterday?
370 (91.4%)
When you feel like your [health concern] is
under control, do you sometimes stop taking
your medicine?
69 (17.0%)
Taking medication everyday is a real
inconvenience for some people. Do you ever
feel hassled about sticking to your [health
concern] treatment plan?
140 (34.6%)
How often do you have difficulty
remembering to take all of your medicine?
Never/rarely 125 (30.9%)
Once in a while 174 (43%)
Sometimes 86 (21.2%)
Usually 14 (3.5%)
All the time 6 (1.5%)
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In the current study, medication adherence and its poten-
tial association with beliefs about medicines and diabetes–
related knowledge was assessed in a selected sample of
Arab Palestinians patients with type II DM. Our results
showed that non-adherence was significantly associated
with diabetes-related knowledge, beliefs about necessity
of the anti-diabetic medications, concerns about adverse
consequences of anti-diabetic medications, and beliefs thatTable 3 Multivariate analysis of factors associated with non-a
Variable β S
Marital status (single) 0.46 0.
High knowledge score −0.14 0.
Presence of other co-morbid disease 0.42 0.
High number of medications consumed per day 0.08 0.
High Specific – necessity score −0.07 0.
High Specific – concern score 0.07 0.
High General – harm score 0.07 0.
Abbreviations: C.I confidence interval, β coefficient of predictor variables, S.E. Standaall medicines are essentially harmful. Our findings regard-
ing association of medication adherence with knowledge
and belief are in agreement with those obtained by other
investigators. Most studies about medication adherence
concluded that negative beliefs about medications is a
powerful barrier to successful adherence [25-31]. There-
fore, healthcare providers should address patient’s beliefs
about medications in the hope of improving medication
adherence and therapeutic outcome. Furthermore, health-
care workers need to assess and educate patients about
diabetes mellitus to improve the level of medication ad-
herence and consequently therapeutic outcome.
The results of our study showed that most diabetic pa-
tients strongly believe that anti-diabetic medications are
necessary for their current and future health. However,
diabetic patients expressed their concerns about the ad-
verse consequences of taking anti-diabetic medications
on regular basis. Similar findings were also reported in
hypertensive patients [32]. Concerns of about long-term
effects of taking anti-diabetic medications should be
addressed by healthcare workers to minimize concerns
and consequently improve medication adherence. Pa-
tients with diabetes mellitus need to know that their
medications are not addictive and that medications have
an acceptable safety profile for long-term use. Studies
have reported that concerns about adverse consequences
medications is independent of patients’ age and level of
education [33]. Therefore, concerns about anti-diabetic
medications need to be addressed regardless of the age
or level of education of the patient. It is important to
note that not all studies endorsed the finding that belief
about medications is an important factor in medication
adherence. For example, a Swedish study concluded that
about one-third of the migraineurs did not adhere to
their prophylactic drugs and that belief about medicines
and medication-related factors could not predict non-
adherence among those patients. The authors recom-
mended further research on medication-related variables
in relation to adherence among migraineurs [34]. These
findings might suggest that the influence of beliefs on
medication adherence is dependent on the type of the
chronic disease.dherence
.E. Wald p-value Odds ratio with 95% C.I
25 3.54 0.060 1.59(0.98-2.56)
06 6.27 0.012 0.87(0.78-0.97)
31 1.83 0.177 1.53(0.83-2.81)
07 1.33 0.249 1.08(0.95-1.24)
03 5.77 0.016 0.93(0.88-0.99)
03 11.86 0.001 1.10(1.04-1.16)
03 7.29 0.007 1.09(1.02-1.16)
rd error.
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total number of medications consumed daily on medi-
cation adherence among diabetic patients. Univariate
analysis showed weak significant association between
total number of medications and medication adherence.
However, this weak significant association disappeared
when strong factors like beliefs and disease-related know-
ledge were entered into the regression model. Further-
more, anti-diabetic regimen (mono versus combination
therapy) showed no significant association with medica-
tion adherence in univariate analysis. This emphasizes the
idea that it is not the total number of medications that
determines level of adherence, rather, it is the belief
about the importance and necessity of medicines for pa-
tient’s life which determines level of adherence. Similar
result was obtained with regard to marital status. Univari-
ate analysis showed that married patients were less likely
to be non-adherent compared to single patients. However
this association disappeared in multiple regression model.
This means that family factors are important for medica-
tion adherence when considered as single factor but such
family factors become insignificant when considered in
the presence of other stronger factors like beliefs and
disease-related knowledge.
In our study we used self-reporting method to measure
medication adherence because it is considered the sim-
plest and the least expensive method. George et al. found
that when a valid scale [35], like Morisky questionnaire, is
used to assess medication adherence, the obtained scores
will be accurate with both sensitivity and specificity of
over 70%. The 8-item Morisky Medication Adherence
Questionnaire (MMAS-8©) has been translated into differ-
ent languages and has been validated in patients with
different types of chronic illnesses [23,36,37]. In our study,
we used “Beliefs about Medicines Questionnaire (BMQ)”
to measure patients’ beliefs about medicines. The BMQ
has been translated into several languages to assess beliefs
about medicines across a wide range of diseases like dia-
betes mellitus, mental health illnesses, rheumatoid arth-
ritis and others [30, 33]. Therefore, tools used in our study
are considered appropriate tools to achieve the stated
objective.
Our study had few limitations. First, a self-report method
was used to assess medication adherence. Therefore,
overestimation of adherence may have occurred. More
precise estimates of medication adherence can be ob-
tained through direct methods. However, self-reported
assessment of medication adherence is practical and
inexpensive. Second, the validity of the Arabic version
of adherence and belief scales has not been tested and
further studies are needed to confirm validity of both
scales among patients in the Arab world. Third, al-
though the sample size was relatively large, it was not
representative of Palestinian or Arab diabetic patients.Therefore, caution should be exercised in generalizing
our findings. Fourth, the selection method might have
created bias toward positive beliefs since patients who
attend to the clinic are those who usually care about
their health. These limitations might be responsible for
the small observed odds ratio. Finally, no glycemic con-
trol data (HbA1C) were obtained. If such piece of infor-
mation was available, then we would be able to link
adherence, beliefs and knowledge with glycemic control.
Conclusions
As a conclusion, beliefs in one’s medications and diabetes-
related knowledge were significantly associated with ad-
herence. Assessment of beliefs and knowledge can be used
to understand variations in adherence among diabetic pa-
tients. The Beliefs about Medicines Questionnaire may be
an appropriate tool to assess beliefs about medicines. Fi-
nally, improving knowledge of diabetic patients about their
illness can positively influence their medication adherence
and therapeutic outcome.
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